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Abstract 
Purpose:  
In radiotherapy, a trade-off exists between computational workload/speed and dose calculation accuracy. 
Calculation methods like pencil-beam convolution can be much faster than Monte-Carlo methods, but less 
accurate. The dose difference, mostly caused by inhomogeneities and electronic disequilibrium, is highly 
correlated with the dose distribution and the underlying anatomical tissue density. We hypothesize that a 
conversion scheme can be established to boost low-accuracy doses to high-accuracy, using intensity 
information obtained from computed tomography (CT) images. A deep learning-driven framework was 
developed to test the hypothesis by converting between two commercially-available dose calculation 
methods: AAA (anisotropic-analytic-algorithm) and AXB (Acuros XB).  
 
Materials & Methods:  
A hierarchically-dense U-Net model was developed to boost the accuracy of AAA dose towards the AXB 
level. The network contained multiple layers of varying feature sizes to learn their dose differences, in 
relationship to CT, both locally and globally. AAA and AXB doses were calculated in pairs for 120 lung 
radiotherapy plans covering various treatment techniques, beam energies, tumor locations, and dose 
levels. For each case, the CT and the AAA dose were used as the input and the AXB dose as the ‘ground-
truth’ output, to train and test the model. The mean-squared-errors (MSEs) and gamma-passing-rates 
(2mm/2% & 1mm/1%) were calculated between the boosted AAA doses and the ‘ground-truth’ AXB 
doses. 
 
Results: 
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The boosted AAA doses demonstrated substantially improved match to the ‘ground-truth’ AXB doses, 
with average(± s.d.) gamma-passing-rate (1mm/1%) 97.6%(± 2.4%), compared to 87.8%(± 9.0%) of the 
original AAA doses. The corresponding average MSE was 0.11(± 0.05) vs 0.31(± 0.21). 
 
Conclusion:  
Deep learning is able to capture the differences between dose calculation algorithms to boost the low-
accuracy algorithms. By combining a less accurate dose calculation algorithm with a trained deep 
learning model, dose calculation can potentially achieve both high accuracy and efficiency.  
 
Key words: Dose calculation, Deep learning, CT, Inhomogeneous regions, AAA, AXB  
 
I. Introduction 
 
In radiation therapy, the radiation doses to the tumor and surrounding normal tissues directly determine 
treatment efficacy and safety [1, 2]. It is pivotal for the radiation therapy treatment planning systems 
(TPSs) to accurately calculate the dose distributions to aid physician’s decisions. Accurate dose 
calculation is also key to a reliable and reproducible model between dose distributions and clinical 
outcomes to guide future treatments [3]. The dose calculation algorithms have seen generations of 
development. The early generations of algorithms, usually referred to as correction-based methods [4-7], 
are barely physics principle-driven. Their accuracy is highly unreliable in heterogeneous regions (for 
instance, areas with lung tissue-surrounding tumors), where the loss of electronic equilibrium occurs [8]. 
To better model the physics in these regions, model-based techniques were developed [9-12]. These 
techniques model the radiation energy transport via dose kernels and convolutions. To account for the 
tissue heterogeneity, the dose kernels are scaled based on the equivalent electron density path lengths 
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encountered by radiation beams, leading to the superposition-convolution type of algorithm, which is 
widely-used in today’s clinic. Analytical anisotropic algorithm (AAA), one of such algorithms, is 
commercially implemented  in the Eclipse TPS [12] (Varian Medical Systems, Palo Alto, CA). However, 
a discrepancy over 5% from measurements can still be observed for AAA in inhomogeneous regions [13], 
which can be clinically significant [14, 15]. The discrepancy is due to the fact that kernel scaling does not 
explicitly and realistically model the energy transport through physical interactions either. The Monte 
Carlo algorithm represents a third type of dose calculation algorithms. It models the transport and energy 
deposition of each particle (photons, electrons, etc.)  via explicit physics principles, which are modeled 
with measured data or proven formula, and provides the highest accuracy [16, 17]. However, Monte Carlo 
needs to simulate the transport of each particle individually, which requires substantial computational 
power and may significantly prolong the dose calculation time. Besides Monte Carlo, recently a new dose 
calculation technique using the linear Boltzmann transport equation was implemented as the Acuros XB 
(AXB) algorithm in Eclipse [18, 19]. It is proven that AXB would theoretically converge to the same 
solution as the Monte Carlo algorithm [20]. The accuracy of AXB has been extensively validated [17, 21, 
22]. The efficiency of AXB is plan-dependent, which improves with increasing beam numbers (relatively) 
and favors volumetric modulated arc therapy plans. In some scenarios, however, AXB can be 10 times 
slower than AAA [23].  
 
In general, a trade-off exists on dose calculation: more accurate dose calculation requires more 
computational power, and is generally more time consuming and resource demanding. Due to this trade-
off, current radiotherapy TPSs may have to use less accurate methods for dose calculation, in order to 
improve efficiency, especially during plan optimization [24]. Such an adoption is less ideal, since these 
low-accuracy dose calculations used during optimization may potentially trap the optimization into a local 
optimum, and yield a sub-optimal final plan. As the radiotherapy society is pursuing more precise, 
individual-tailored treatments, the use of low-accuracy dose calculation algorithms for plan optimization 
may fail to generate high-quality plans within a tight time frame, especially for on-line adaptive 
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radiotherapy [25]. A technique enabling dose calculation with both high accuracy and efficiency is thus 
much desired for plan optimization. In addition, recent advancements of real-time imaging techniques 
also call for such a technique [26], which will make possible on-the-fly dose monitoring and intervention 
through real-time plan re-optimization and adaptation.  
 
As mentioned, the differences between low-accuracy and high-accuracy doses are mostly within 
inhomogeneous regions. The inhomogeneity, however, is fully-captured in simulation CT images that are 
used for dose calculation. From this observation, we hypothesize that the differences between dose 
algorithms can be learned and correlated with the dose distribution and the CT intensity information. With 
this learnt correlation, we can then quickly boost the low-accuracy doses to high-accuracy, to overcome 
the trade-off between dose calculation accuracy and efficiency. Recently, the developments and 
applications of artificial intelligence (AI) in radiation therapy have seen tremendous growth [27-32]. 
Sophisticated convolutional neural networks can handle intensive tasks including medical image de-
noising, segmentation, treatment plan optimization/evaluation, and clinical outcome prediction. Some 
networks, including the U-Net [33], can perform voxel-wise prediction and mapping, which allows a 
potential voxel-to-voxel dose map conversion to boost the accuracy of low-accuracy doses. Additionally, 
the U-Net can extract both global and local features from dose distributions and CT images, which can be 
directly correlated with dose differences between algorithms, as the energy transport is essentially 
determined by both long-range (global) photon transport and short range (local) electron transport. With 
dedicated graphics processing units (GPUs), the inference of U-Net can also be executed within seconds, 
meeting the efficiency requirement.  Driven by our hypothesis, in this study we introduced an AI-based 
framework to achieve rapid, direct 3D dose map conversion from low-accuracy doses to high-accuracy 
doses. We trained and evaluated the whole framework on AAA (“low-accuracy”) and AXB (“high-
accuracy”) dose maps to demonstrate its effectiveness, since these two algorithms are well-studied, 
widely-available and can be easily evaluated by other groups. Note that the “low-accuracy” and “high-
accuracy” here were defined relatively, since under different context and scenarios, AAA can also be 
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high-accuracy (for instance when compared with pencil-beam convolution), and AXB may be low-
accuracy when compared with a full-fledged Monte-Carlo package. The “high” and “low” here thus were 
determined relatively between the two algorithms under study. We derived and tested the dose conversion 
model using a large lung cancer patient database, aiming to improve the dose calculation of lung cancer 
treatment, whose accuracy is the most susceptible to tissue inhomogeneity [28].  
 
 
II. Materials and Methods 
 
II.1. Data preparation 
 
In this study, we retrospectively collected a total of 120 lung cancer patient cases in our institution treated 
between 06/2017 and 03/2018. The retrospective study was approved under an institutional review board 
umbrella protocol. All patients were planned in Eclipse V15.5, by techniques ranging from 3D non-
coplanar conformal static beams, intensity modulated static beams, 3D conformal arcs to volumetric 
modulated arcs. The total prescription doses ranged from 24 Gy to 60 Gy, covering both conventional and 
stereotactic body radiation therapy treatments. The tumors were distributed across both central and 
peripheral lung regions. Both primary lung tumors and metastatic tumors from breast, liver, kidney and 
prostate were included. The treatment plans used beam energies ranging from 6 MV, 10 MV, 6 MV FFF 
to 10 MV FFF. All treatments were designed and successfully delivered on an Elekta VersaHD LINAC 
with a 160-leaf Agility multi-leaf-collimator head [34]. All cases were planned and treated using AAA as 
the dose calculation engine, with heterogeneity correction turned on. The dose grid was 2.5 mm x 2.5 mm 
x 2.0 mm in resolution. 
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For each AAA dose distribution, we calculated the corresponding AXB dose distribution under the exact 
same plan. The AXB doses were reported in the form of dose to medium to account for the elemental 
composition of different tissues. In Eclipse, the tissue designation is based on the densities determined 
from CT Hounsfield units. The corresponding elemental composition of each tissue is then determined on 
the basis of the International Commission on Radiological Protection Report 23 [35]. The dose grid of 
AXB was 2.5 mm x 2.5 mm x 2.0 mm in resolution, same as AAA. For each patient, we also exported the 
planning CT volume. The planning CT volumes were of varying voxel resolutions and volumetric 
dimensions for different patient cases. We exported the CT and dose files as DICOM-RT files from 
Eclipse, registered them with DICOM coordinates, and converted them into numeric arrays for the 
training, validation and testing purposes. Prior to feeding them into the neural network, we rescaled and 
interpolated both the AAA and AXB doses, as well as the patient-specific CT volumes to a uniform 
resolution of 1.37 mm x 1.37 mm x 2 mm. 
 
II.2. Network structure selection 
 
For efficient and accurate dose boosting, we employed a Hierarchically Dense U-Net (HD U-Net) 
structure [30]. HD U-Net is a combined version of U-Net and DenseNet [36]. Compared with U-Net, HD 
U-Net uses densely connected layers within each hierarchical level of U-Net, which helps with feature 
propagation and reuse, and reduces the vanishing gradient issue. Compared with DenseNet, HD U-Net 
preserves the pooling and up-sampling procedures of U-Net, which are able to capture the global features 
from the input. Once the HD U-Net structure is set, it trains the same way as U-Net. Quantitative 
comparisons between the three type of networks have been reported and well-documented in a previous 
publication [30], showing the advantage of the HD U-Net. As reported, HD U-Net was able to achieve 
high accuracy with much fewer parameters in the network than U-Net, which reduced the chance of over-
fitting. In contrast, DenseNet provided the overall worst results due to its lack of ability in capturing 
global features. For the supervised training, input channels for the HD U-Net include the Eclipse-
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calculated AAA dose distribution and the CT volume, and the ‘ground-truth’ output is the Eclipse-
calculated AXB dose distribution. For testing, the output will be the boosted dose. We used patch-based 
training [37] to balance the size of the training data and the computational resources. We separated the 
full dose volume (512 x 512 x 128) into patches (patch size: 512 x 512 x 16), and feed each of them 
individually into the network for training/testing. We then merged the output dose maps into a single 
volume as the final output. The overall training and testing framework is illustrated in Fig. 1. 
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Figure 1. (a) General framework of the HD U-Net model for the proposed dose accuracy boosting 
technique. (b) General training and testing processes where the patient-specific CT and low-accuracy 
AAA doses serve as the input into the HD U-Net structure, and the high-accuracy AXB doses serve as the 
‘ground-truth’ output for supervised training/validation. Using the trained framework, a new patient-
specific CT and low-accuracy AAA dose can be input to obtain a high-accuracy, boosted AAA dose as 
the output, with its accuracy matching the AXB dose level. 
 
II.3. Training and testing 
 
Out of the 120 paired, patient-specific AAA-AXB dose maps, we randomly selected 72 sets for training, 
18 for validation during training and another 30 for testing. The deep learning model was trained with its 
hyper-parameters tuned using the validation data set. The HD U-Net contained a hierarchy of five levels 
to reduce the feature size down to 8 x 8 x 1 at the bottom layer with 2 x 2 x 2 inter-layer max pooling, to 
learn both local and global features. Within each layer, the convolutional kernel of size 3 x 3 x 3 was 
implemented with zero padding to maintain the feature size. On the first half of the U-Net, 16 feature 
maps (filters) were generated in each convolution step. On the remaining half, the number of feature maps 
of convolution in each layer, except for the very last convolution step, increased by 16 features from the 
bottom to the top. The last convolution step generated one channel as the final output. Batch 
normalization was applied after convolution with rectified linear unit (ReLU) operations. The learning 
rate was set at 10
-4
 and the Adam algorithm [38] was selected as the optimizer to minimize the loss 
defined using the mean-squared-error (MSE). 200 epochs were used for the training in our study, with 
100 iterations per epoch. The deep learning model was trained on one NVIDIA Tesla V100 GPU card 
with 32GB dedicated memory. 
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To assess the accuracy of the boosted AAA dose map, we visually evaluated its difference with the AXB 
dose map directly calculated from Eclipse. MSEs were computed between the boosted AAA and AXB 
dose maps to evaluate their differences. 3D gamma analysis [39]  based on both 1%/1mm and 2%/2mm 
criteria was also performed to quantitatively assess the match between the boosted AAA and AXB dose 
distributions. We also compared the dose volume histograms (DVHs) of the planning target volume 
(PTV) and lungs between boosted AAA and AXB doses to evaluate the accuracy of dose conversion. 
Quantitative dosimetric endpoints, including the D95 and V100 of the PTV, and V20Gy and Dmean of the 
lungs, were also assessed. The corresponding results between original AAA doses (prior to boosting) and 
AXB doses were also computed for comparison.  
 
In addition to the proposed network with both original AAA dose and CT as input, we also evaluated a 
second network using only the original AAA dose as input. The second network was evaluated to assess 
the potential of directly learning intensity, texture and structural information from the low-accuracy dose 
maps, to correlate with high-accuracy dose maps for dose boosting. The second network was trained and 
tested with the same AAA-AXB dose map pairs. 
 
 
III. Results 
 
Fig. 2 shows the relative differences between the original AAA and AXB doses (Fig. 2 (b) and Fig. 2 (e)), 
and between the boosted AAA and AXB doses (Fig. 2 (c) and Fig. 2 (f)), on three views (coronal, sagittal, 
and axial). Figs. 2 (a) - 2 (c) present a representative non-coplanar static beam plan case, and Figs. 2 (d) – 
2 (f) present a volumetric modulated arc plan case. For both cases, the original AAA dose maps show 
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prominent deviations from the reference AXB doses. These dose deviations were substantially reduced in 
the boosted AAA dose maps.  
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Figure 2. (a) The ‘ground-truth’ AXB dose maps and relative differences between (b) the original AAA 
and AXB dose maps; (c) the boosted AAA and AXB dose maps, for a 3D non-coplanar static beam plan. 
(d) The ‘ground-truth’ AXB dose maps and relative differences between (e) the original AAA and AXB 
dose maps; (f) the boosted AAA and AXB dose maps, for a volumetric-modulated arc plan. The ‘ground-
truth’ AXB doses were shown in absolute quantities (Gy). The dose differences were normalized to the 
plan prescription dose (%). 
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Figure 3. Gamma index (1%/1mm) maps between the original AAA and AXB dose distributions, and 
between the boosted AAA and AXB dose distributions for (a) a 3D non-coplanar static beam plan, and (b) 
a volumetric-modulated arc plan. The color bar on the right shows the scale of gamma index and the 
dashed lines indicate the PTVs. A gamma index > 1 indicates failed gamma test. 
 
In Fig. 3 we showed the gamma index maps between the original AAA and AXB dose distributions, and 
between the boosted AAA and AXB dose distributions for a 3D non-coplanar static beam plan (Fig. 3 (a)) 
and a volumetric-modulated arc plan (Fig. 3 (b)), respectively. A stringent criterion (1%/1mm) was used 
to fully demonstrate the differences between dose maps. The red regions in the map indicated failed 
gamma index (>1). Large dose discrepancies can be observed on the original AAA gamma index maps, 
especially around the tumor region. As a comparison, the gamma index maps of the boosted AAA dose 
have these discrepancies largely removed. 
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Figure 4. The DVH curves of PTV and lungs for (a) a 3D non-coplanar static beam plan, and (b) a 
volumetric-modulated arc plan. (c) shows the zoomed-in lung DVH curves for the volumetric-modulated 
arc plan. The solid, dashed and dotted lines correspond with the AXB, boosted AAA, and original AAA 
dose maps, respectively. 
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Fig. 4 compared the DVH curves between the original AAA, AXB, and boosted AAA dose distributions, 
for both PTV and lungs. The DVH curves of boosted AAA doses matched well with those of AXB doses, 
while substantial discrepancy could be observed between DVH curves of the original AAA and AXB 
doses. 
 
Table 1. Quantitative comparisons between the original AAA and AXB doses, and between the boosted 
AAA (w/ and w/o CT as input) and AXB doses. MSE: mean-squared-error. RX: prescription. The results 
of the 30 testing patient cases were included in the analysis. 
 
 
Dose maps 
Gamma passing rates (%) MSE of voxels 
with dose > 5% 
RX dose  
% of voxels with 
dose deviations > 
3% RX dose  2mm/2% 1mm/1% 
Original AAA vs. AXB 98.4 ± 1.5 87.8 ± 9.0   0.31±0.21 2.01 ± 1.19 
Boosted AAA w/o CT vs. AXB 99.3 ± 0.7 94.6 ± 2.8 0.15±0.10 0.85 ± 0.53 
Boosted AAA vs. AXB 99.8 ± 0.4 97.6 ± 2.4 0.11±0.05 0.46 ± 0.46 
 
 
In Table 1, the boosted AAA doses demonstrated substantially improved match to the AXB doses, with 
average (± s.d.) gamma passing rate (1 mm/1%) 97.6% ± 2.4%, compared to 87.8% ± 9.0% for the 
original AAA doses. Using a less strict criterion (2 mm/2%) yielded 99.8% ± 0.4% for the boosted AAA 
doses, compared to 98.4% ± 1.5% for the original AAA doses. The corresponding average MSE was 0.11 
± 0.05 between the boosted AAA and AXB doses, compared to 0.31 ± 0.21 between the original AAA 
and AXB doses. The boosted AAA doses (w/o CT as input) were of accuracy in between the original 
AAA doses and the boosted AAA doses. Note that since this paper focuses on developing a network 
using CT as one of the input, if not specifically mentioned, boosted AAA doses refer to those obtained 
from this network. 
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Table 2. Comparisons between the original AAA, AXB, and boosted AAA doses in terms of D95 of PTV, 
V100 of PTV, Dmean of lungs, and V20Gy of lungs. The results of the 30 testing patient cases were included 
in the analysis. 
PTV 
 
D95 (Gy) V100  
 
Original AAA AXB 
Boosted 
AAA 
Original AAA AXB 
Boosted 
AAA 
Mean 45.00 44.43 44.40 94.48% 89.40% 89.71% 
s.d. 7.82 7.94 7.84 0.98% 10.73% 8.50% 
Lungs 
 
Dmean (Gy) V20Gy 
 
Original AAA AXB 
Boosted 
AAA 
Original AAA AXB 
Boosted 
AAA 
Mean 4.49 4.42 4.41 5.89% 5.84% 5.85% 
s.d. 2.61 2.57 2.58 4.43% 4.37% 4.39% 
 
In Table 2, dosimetric comparison results were reported in terms of D95 of PTV, V100 of PTV, Dmean of 
lungs, and V20Gy of lungs. Wilcoxon signed-rank tests with the Bonferroni corrections revealed that the 
AXB was significantly distinct from the original AAA in Dmean of lungs (p-value < 10
-5
), D95 of PTV (p-
value = 0.001), and V100 of PTV (p-value = 0.002). In contrast, the boosted AAA did not statistically 
differ from the AXB (p-value = 0.094 for Dmean of lungs, p-value = 0.642 for D95 of PTV, and p-value = 
0.417 for V100 of PTV). No significant differences were found for V20Gy of lungs, either for the boosted 
AAA and AXB pair, or the original AAA and AXB pair. Therefore, the boosted AAA matched better 
with AXB than the original AAA doses, which provided more accurate target coverage and OAR sparing 
information.  
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IV. Discussion 
 
Accurate dose calculation and reporting are key to effective and safe radiation therapy. A dose calculation 
algorithm with both high accuracy and high efficiency is much desired in today’s clinic for treatment 
planning and dose reporting. Our study demonstrated that through a deep learning framework, we could 
achieve a high-accuracy dose map by boosting from a low-accuracy dose map with patient-specific 
anatomical CT information, to successfully overcome the trade-off between computational speed and 
accuracy. The training of our deep learning model takes around ~48 hours for 200 epochs. Currently, the 
inference of our deep learning model takes on average 19 seconds, with a standard deviation of 3 seconds. 
The relatively long inference time is mostly due to the memory limit of our GPU hardware. Under the 
memory limit, we have to use a patch-based strategy to boost the AAA dose patch by patch, and then 
merge the results together for a full dose volume. With a larger GPU memory, we can boost the whole 
AAA dose volume by running the model only once, which takes roughly 1-2 seconds. In addition, in this 
study we performed dose boosting on an AAA dose volume of 512 x 512 x 128 voxels, while the 
meaningful dose cloud only occupies a much smaller region within. We may trim the AAA dose volume 
to remove the irrelevant regions of minimal doses, and apply the deep learning model to the remaining 
dose cloud only. By this way, we can also remove the need of patch-based model inference and accelerate 
dose boosting to ~1 second. To put the dose boosting time into context, for our AAA dose and AXB dose 
calculations, we found the AXB calculation was around 1.5 to 5 times slower than the AAA calculation, 
depending on the treatment technique and beam arrangement of each plan. In terms of seconds/minutes, 
AXB can be ~30 seconds to more than two minutes slower than AAA. In general, AXB tends to be much 
less efficient for plans with static-gantry beams, which are frequently used in our clinic for lung 
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treatments. Our dose boosting scheme, which can potentially be executed within 1 second, will 
significantly improve the dose calculation efficiency.  
 
In this study, we trained, validated and tested a voxel-wise dose boosting model on 120 in-house lung 
cancer patient cases using a Hierarchically Dense U-Net. Visual comparisons of dose differences showed 
major improvements in the boosted AAA doses, for areas both within the tissues and along tissue 
interfaces (Fig. 2). In comparison, the original AAA lacks accuracy in calculating doses at multiple 
regions, where electron densities are changing rapidly and invalidate the kernel scaling approach it 
applied to account for tissue inhomogeneity. Gamma index distribution maps shown in Fig. 3 also 
confirmed the improvement of accuracy in boosted AAA doses. The structural-specific DVH curves and 
dosimetric endpoints also demonstrated that the boosted AAA doses matched well with the AXB doses 
(Fig. 4, Table 2), and provided more accurate target coverage and OAR sparing information. In general, 
the conversion model yielded ~98% gamma passing rate between the boosted AAA and AXB doses for 
1%/1mm gamma analysis and ~100% gamma passing rate for 2%/2mm gamma analysis, showing almost 
perfect match. In comparison, the corresponding results were only ~88% and ~98% for the original AAA 
doses (Table 1).  
 
In our developed network, we used both CT images and a low-accuracy dose map as input to derive a 
high-accuracy dose map. We also evaluated the feasibility of directly using the low-accuracy dose map 
(w/o CT) to correlate with the high-accuracy dose map for dose boosting (Table 1). It can be observed 
that the network without using CT as input also helps to boost the AAA dose to match better with the 
AXB dose than the original AAA dose. However, it is also evident that the boosted AAA dose with CT as 
input has its accuracy best matched with the AXB dose. With the CT images providing electron density 
information, the HD U-Net will be better informed of potential inaccuracies in the original AAA dose 
maps through interpreting the CT density information, to further improve the accuracy of dose boosting.  
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In current clinical practice, convolution/superposition algorithms like AAA remain the main dose 
calculation engine for clinical TPS. To improve the dose calculation accuracy, AXB has been introduced 
into clinics as an alternative to full Monte Carlo simulation, but its clinical use is still limited. Potential 
hurdles include the acquisition cost, the lack of resources, the lack of experience to commission a new 
AXB engine, and often, the physicians’ familiarity and reliance with AAA doses upon which the clinical 
experience was accumulated. However, it is always highly desirable to use the most accurate dose 
distribution to correlate with clinical outcomes, in order to derive a reliable and reproducible dose-
outcome relationship to benefit and guide future practices. The dose boosting model developed by us can 
contribute to this goal, as it could be easily adopted by clinics to prospectively/retrospectively convert the 
original AAA doses to AXB-quality doses. The potential fast-speed conversion (within seconds) 
introduces minimal interference towards current clinical workflow. The model could be incorporated into 
the TPS’s application programming interface (API)  (e.g. ESAPI) [40], to enable direct dose conversion 
with a one-click solution to allow physicians to evaluate and compare the original AAA and boosted 
AAA doses side-by-side. Currently, our model is built and run on Python, an interpreted, general-purpose 
programming language. To run our model in Eclipse, one way is to compile our Python code into an 
executable, and call the executable from within Eclipse using scripts. There are also ongoing 
developments on a Python interface for ESAPI, which could make an alternative path to run our model 
within Eclipse. The model could also be run in batch in the background to accumulate boosted AAA data 
for further dose-clinical outcome analysis. The dose conversion model also does not incur costs 
associated with proprietary dose calculation algorithms, which can potentially benefit less resourceful, 
under-served cancer centers. We believe the accuracy and convenience offered by the dose map 
conversion framework will help physicians to make a more informed decision when evaluating treatment 
plans, and ultimately benefit the current radiotherapy practice with more accurate dose calculations 
especially in heterogeneous regions [41].  
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In this study, all the evaluated patient data sets are acquired from our institution. The developed model 
needs to be further evaluated on patient data sets from other institutions to assess its transferability. 
Though no substantial model adjustments are expected, some slight model tweaking might be needed to 
accommodate the inter-institutional variations. Transfer learning, an artificial intelligence technique that 
allows easy model adaptation based on limited new data samples, may help in the case [28]. Similarly, all 
our data are currently trained on lung cancer patients, other clinical scenarios where the inhomogeneity 
might affect the dose accuracy, such as larynx and pelvis [42], also warrant additional model evaluation 
and potential model fine-tuning.   
 
In addition to our study, there are other groups working on projects to uncover the potential of deep 
learning in dose accuracy enhancement. A recent work by [1] uses parallel U-Net branches to boost 
Monte-Carlo dose calculation accuracy. However, this method is currently limited to boosting doses 
calculated by a single beamlet, as compared to the full 3D dose map boost achieved by our method. In 
addition, the network developed by [1] works by boosting low-accuracy Monte-Carlo doses (fewer 
events: faster calculation, more noise, more uncertainty) to high-accuracy Monte-Carlo doses (more 
events: slower calculation, less noise, less uncertainty), essentially an intra-algorithm conversion 
(between same Monte-Carlo type algorithms). In comparison, our method can boost the doses from one 
type of algorithm to another (AAA to AXB in our study), allowing inter-algorithm conversion. Another 
study by [2] is also converting between low-accuracy and high-accuracy Monte-Carlo doses for de-
noising, which may not be readily applicable to non-Monte-Carlo based dose calculation algorithms 
which are dominant in current clinical TPSs. 
 
In summary, it is shown in this study that with the power of deep learning, we can uncover a mapping 
scheme between low-accuracy and high-accuracy dose maps, using patient anatomical structure maps and 
intensity distributions as guidance. The “low” and “high” are defined only relatively in the context of the 
two algorithms under study, and should not be interpreted in an absolute fashion. We tested this 
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hypothesis through developing and evaluating a dose boosting framework between AAA and AXB dose 
maps. This framework can be readily extended to other potential pairs of dose maps, the relative accuracy 
difference of which may be more pronounced. The relative accuracy levels of different algorithms can be 
determined through the four types of algorithms defined in the AAPM Task Report No. 85 [1], or the ‘a’ 
to ‘c’ categories stratified by [45].  It will be of interest to test the framework in boosting pencil-beam 
convolution doses to Monte-Carlo doses, which might have a positive impact on treatment plan 
optimization as less-accurate pencil-beam convolution-type calculations are usually used within 
optimization to promote efficiency.  It also remains to be investigated how robust the current framework 
will be to boost a rudimentary algorithm (such as the correction-based dose calculation algorithm) to a 
high-accuracy algorithm like Monte Carlo. Additional information, like the treatment plan itself, could be 
potentially fed into the AI framework to improve the dose boosting accuracy if needed.  
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